For that reason, researchers suggested the use of AGTR1 (AT1R) antagonists like losartan and olmesartan and other angiotensin II receptor blockers (ARBs) as a possible tentative therapeutic option for COVID-19 infection that may protect COVID-19 patients from the severe symptoms and reduce their mortality rate (Gurwitz, 2020; Sun et al., 2020). The gene discussed is AGTR1; the disease is COVID-19.